Exelixis reported $88.51M in Pre-Tax Profit for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Pre Tax Profit Change
Acadia Pharmaceuticals ACAD:US $ -33.57M 79M
Agios Pharmaceuticals AGIO:US $ -91.81M 2.97M
Biomarin Pharmaceutical BMRN:US $ 34.85M 8.66M
Bluebird Bio BLUE:US $ -100.14M 22.01M
Cytokinetics CYTK:US $ -19.82M 66.93M
Eisai 4523:JP Y 9722M 30501M
Esperion Therapeutics ESPR:US $ -66324000 9.59M
Exelixis EXEL:US $ 88.51M 3.28M
Genmab GEN:DC DK 612M 354M
Immunogen IMGN:US $ -62.02M 37.88M
IONIS PHARMACEUT IONS:US $ -103M 39M
Macrogenics MGNX:US $ -41.3M 25.14M
Mirati Therapeutics MRTX:US $ -176.44M 11.94M
Nektar Therapeutics NKTR:US $ -158.97M 68.7M
Neurocrine Biosciences NBIX:US $ -23.3M 44.7M
Novartis NOVN:VX SF 4129M 217M
Takeda 4502:JP Y 155473M 209520M
Ultragenyx Pharmaceutical RARE:US $ -157.86M 6.1M
Xencor XNCR:US $ -33.98M 57.57M